Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
Receive an email update when we add a new AGE-RELATED MACULAR DEGENERATION article.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- US trial of Notal Vision’s home-based OCT underway on December 18, 2018 at 8:15 am
Notal Vision has initiated the first U.S. clinical study of its patient-operated OCT system that can be used at home to monitor wet age-related macular degeneration, the company announced in a press r... […]
- Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 on December 18, 2018 at 6:00 am
The Company initiated its first clinical trial for ONS-5010, a proprietary ophthalmic bevacizumab product candidate, in patients with wet age related macular degeneration (wet AMD). The study is ... […]
- AMD Monitoring Comes Home: The Promise of Innovative Remote Tech on December 17, 2018 at 8:08 am
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, or the central part of the retina, which ha... […]
- Nitrates may lower risks of age-related macular degeneration on December 17, 2018 at 6:44 am
An observational study has shown an association between eating vegetable nitrates, found in green leafy vegetables and beets, and a lower risk of developing an early stage of age-related macular degen... […]
- Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration on December 17, 2018 at 4:30 am
SAN CARLOS, Calif., Dec. 17, 2018 /PRNewswire/ -- Alkahest Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced to... […]
- BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States on December 16, 2018 at 10:30 pm
and MACUNEOS through our MACA study program in dry age-related macular degeneration (AMD)." Mr. Schneiderman stated: "I am thrilled to join the leadership team at BIOPHYTIS at such an exciting ... […]
- U.S. Age-Related Macular Degeneration: 2018 Market and Competitive Landscape - ResearchAndMarkets.com on December 12, 2018 at 12:42 am
The "U.S. Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights into Age-Rel... […]
- Age-Related Macular Degeneration Market Is Expected to Expand at an Impressive Rate by 2025 on December 11, 2018 at 10:47 pm
Albany, NY -- (SBWIRE) -- 12/12/2018 -- Age-Related Macular Degeneration is also called macular degeneration, ARMD, or AMD. AMD is a disease of retina that blurs the sharp central vision, which is imp... […]
- Age Related Macular Degeneration Market 2018 – It is predicted to reach US$ 2200 Million to Unlock Growth Opportunities by 2023 on December 11, 2018 at 4:49 am
Market Research Future (MRFR) in its recently published study report asserts that the already booming market of Age Related Macular Degeneration is expected to gain prominence over the forecast period ... […]
via Bing News